Veeva Systems Inc.
VEEV Large CapHealthcare · Health Information Services
Mis à jour: Jun 18, 2026, 22:21 UTC
Price Chart
Indicateurs clés
Valuation Analysis
About the Company
Veeva Systems Inc. en bref
Veeva Systems Inc. (VEEV) is currently trading at 133,84 € with a market capitalization of 21,7 Md €. The trailing P/E ratio stands at 27.19x, with a forward P/E of 15.28x. The 52-week range spans from 129,20 € to 270,97 €; the current price is 50.6% below the yearly high. Year-over-year revenue growth stands at +16.3%. The net profit margin stands at 28.37%.
💰 Dividende
Veeva Systems Inc. currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.
📊 Avis des analystes
27 analystes évaluent Veeva Systems Inc. (VEEV) au consensus : Acheter. L'objectif de cours moyen est de 214,22 €, soit un potentiel de +60.06% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 143,99 € à 305,44 €.
Veeva Systems Inc. : la thèse d'investissement en détail
Veeva Systems Inc. (VEEV) operates in the Healthcare — specifically Health Information Services — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.
Le scénario haussier
Revenue is growing at a healthy 16.3% pace year-over-year, suggesting the business model continues to find new customers and pricing power. With a gross margin near 75.02%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns. Free cash flow is positive and net margins stand at 28.37%, meaning reported earnings translate into real cash that can fund buybacks, dividends or strategic acquisitions.
Valorisation en contexte
With a PEG ratio of 0.74, the price-to-earnings multiple is actually below the company's growth rate — classic value-meets-growth territory that Peter Lynch would have called a 'GARP' opportunity.
À surveiller
- The forward P/E of 15.28x is meaningfully below the trailing 27.19x — analysts expect earnings to step up; the next earnings release is the test.
- The price sits in the lower quartile of the 52-week range — value hunters often start scaling in around this zone if fundamentals hold.
- The analyst consensus price target implies 60.06% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.
Thèse d'investissement : forces et faiblesses
- Rentable avec une marge nette de 28.37%
- Marge brute élevée de 75.02% — signe d'un pouvoir de fixation des prix
- Consensus des analystes : Buy
- Bilan solide avec faible endettement (D/E 1.41)
- Free cash flow positif
Aucun signal d'alerte significatif dans les indicateurs actuels.
Aperçu technique
Price is below both the 50- and 200-day moving averages, with 50d below 200d — a bearish picture (death-cross alignment).
Profil de risque
The data points to relatively defensive market behavior, elevated short interest (5.9%).
Trading Data
Related Stocks in the Same Sector
More Santé stocks
Top peers in the same sector — ranked by market cap.
Where can I buy Veeva Systems Inc.?
Compare top-rated brokers — low fees, trusted providers, fully regulated.
Live Market Data
Real-time chart, financials, earnings, analysts, insider trades, events & news
